Merck Ahead of Earnings

Published on Wednesday, 01 February 2012 11:48 Written by Gerard Lerod

New York, February 1st (TradersHuddle.com) - Shares of Merck & Co. Inc. (NYSE:MRK) are trading higher by +1.41% ahead of its quarterly earnings release. Merck, the maker of Singulair and Zocor is expected to release its quarterly results on January 2^nd.

Wall Street Analysts consensus calls for a profit of $0.95 a share on $12.53 billion revenue.

Merck estimates have a range of $0.04 a share. The high estimate calls for profit of $0.97 a share and the low estimate is calling for a profit of $0.93 a share, a year ago for the quarter the company reported $0.88 a share.

Merck & Co., Inc. (NYSE:MRK), the global pharmaceutical company that develops, manufactures, and markets a broad range of human and animal health products. Merck's products include Zocor for treatment of elevated cholesterol, Propecia for treatment for male pattern hair loss, Fosamax for preventive treatment of osteoporosis, and Singulair for treatment of asthma. Merck was founded in 1891 and is headquartered in Whitehouse Station, New Jersey.

Other companies on the watch on this earnings event are Pfizer, Inc. NYSE:PFE and Bristol-Myers Squibb Company NYSE:BMY.